Millendo Therapeutics to Participate in September Investor Conferences

ANN ARBOR, Mich.--(BUSINESS WIRE)-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:

Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5, 2019 (one-on-one meetings only)
Location: Boston, MA

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
Date: Monday, September 23, 2019 (one-on-one meetings only)
Location: New York, NY

Ladenburg Thalmann 2019 Healthcare Conference
Date/Time: Tuesday, September 24, 2019 at 11:00 a.m. EDT
Location: New York, NY

A live webcast of the Ladenburg Thalmann presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190829005139/en/

Millendo Investor Contact:
Stephanie Ascher
Stern Investor Relations
212-362-1200
[email protected]

Millendo Media Contact:
Betsy Yates
MacDougall
781-235-3094
[email protected]

Source: Millendo Therapeutics, Inc.

You May Also Be Interested In

• Rio Tinto celebrates 60 years in Western Australia
• TOZO AIVU AI Glasses Surpass $100,000 on Kickstarter with Tinted Waveguide Innovation
• Granite Asia Ranked No. 1 Top Asset Manager in Asia for 2026, Metaclade Research Finds